<DOC>
	<DOCNO>NCT02060188</DOCNO>
	<brief_summary>The purpose study examine Nivolumab , Nivolumab combination anti-cancer drug , result meaningful tumor size reduction , patient colon cancer come back spread , specific biomarker tumor .</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study Nivolumab , Nivolumab Combination With Other Anti-cancer Drugs , Colon Cancer That Has Come Back Has Spread</brief_title>
	<detailed_description>Allocation : The Microsatellite Instability High ( MSI-High ) C4 Cohort Parts trial Non-randomized , The Non-MSI high Dose Escalation Phase part trial contain randomized portion</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men woman â‰¥ 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically confirm recurrent metastatic colorectal cancer Measurable disease CT MRI Testing MSI Status ( accredit lab ) 1 . Subjects microsatellite instability high ( MSIH ) tumor enroll MSIH Cohort ( mStage cStage group ) , C3 Cohort , C5 Cohort . 2 . Subjects phenotypes nonmicrosatellite instability high ( nonMSIH ) enroll non MSIH Safety Cohort C6 Cohort . Adequate organ function define studyspecific laboratory test Must use acceptable form birth control throughout study . After final dose study drug , acceptable form birth control must use 23 week woman childbearing potential ( WOCBP ) 31 week men sexually active WOCBP Signed inform consent Willing able comply study procedure Subjects enrol C3 Cohort must treatment metastatic disease Active brain metastasis leptomeningeal metastasis allow . Prior treatment antiProgrammed Death Receptor ( PD ) 1 , antiPDL1 , antiPDL2 , antiCytotoxic TCell Lymphoma4 Antigen ( CTLA4 ) antibody , antibody drug specifically target Tcell costimulation immune checkpoint pathway Prior malignancy active within previous 3 year except locally curable cancer Subjects active , know suspected autoimmune disease Subjects condition require systemic treatment either corticosteroid immunosuppressive medication within 14 day study drug administration Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>